首页> 外文期刊>Cells tissues organs >Fibrin gel-immobilized primary osteoblasts in calcium phosphate bone cement: in vivo evaluation with regard to application as injectable biological bone substitute.
【24h】

Fibrin gel-immobilized primary osteoblasts in calcium phosphate bone cement: in vivo evaluation with regard to application as injectable biological bone substitute.

机译:磷酸钙骨水泥中纤维蛋白凝胶固定的原代成骨细胞:关于作为可注射生物骨替代物的应用的体内评估。

获取原文
获取原文并翻译 | 示例
       

摘要

Osteogenic injectable bone substitutes may be useful for many applications. We developed a novel injectable bone substitute based on osteoblast-fibrin glue suspension and calcium phosphate bone cement (BC). Human osteoblasts were isolated from trabecular bone samples and cultured under standard conditions. Osteoblasts were suspended in fibrinogen solution (FS). BC was cured with thrombin solution. 8 x 4 mm injectable bone discs were prepared using silicon molds and a custom-made applicator device. Discs containing BC, BC/FS, or BC/FS/osteoblasts were implanted subcutaneously into athymic nude mice. After 3, 9 and 24 weeks, specimens were explanted and subjected to morphologic and biomechanical evaluation. In vitro fibrin gel-embedded osteoblasts displayed a differentiated phenotype as evidenced by alkaline phosphatase, collagen type 1 and von Kossa stains. A proportion of osteoblasts appeared morphologically intact over a 3-day in vitro period following application into the BC. BC/FS and BC/FS/osteoblast discs were sparsely infiltrated with vascularized connective tissue. There was no bone formation in implants from all groups. However, positive von Kossa staining only in BC/FS/osteoblast groups suggests engraftment of at least some of the transplanted cells. Biomechanical evaluation demonstrated initial stability of the composites. Young's modulus and maximal load did not differ significantly in the BC/FS and BC/FS/osteoblast groups. The practicability of osteoblast-containing injectable bone could be demonstrated. The dense microstructure and the suboptimal initial vascularization of the composites may explain the lack of bone formation. Modifications with regard to enhanced osteoblast survival are mandatory for a possible application as injectable osteogenic bone replacement system.
机译:成骨性可注射骨替代物可用于许多应用。我们开发了一种基于成骨纤维蛋白胶悬浮液和磷酸钙骨水泥(BC)的新型可注射骨替代物。从小梁骨样品中分离出人成骨细胞,并在标准条件下进行培养。成骨细胞悬浮在纤维蛋白原溶液(FS)中。 BC用凝血酶溶液固化。使用硅模和定制的涂药器准备8 x 4 mm的可注射骨盘。将包含BC,BC / FS或BC / FS /成骨细胞的椎间盘皮下植入无胸腺裸鼠中。 3、9和24周后,将标本移出并进行形态和生物力学评估。体外纤维蛋白凝胶包埋的成骨细胞表现出分化的表型,碱性磷酸酶,1型胶原和von Kossa染色证明了这一点。应用到BC后,在体外的3天时间内,一部分成骨细胞在形态上是完整的。 BC / FS和BC / FS /成骨细胞盘稀疏地渗入有血管的结缔组织。所有组的植入物均无骨形成。但是,仅在BC / FS /成骨细胞组中阳性von Kossa染色提示至少移植了一些移植细胞。生物力学评估证明了复合材料的初始稳定性。在BC / FS和BC / FS /成骨细胞组中,杨氏模量和最大载荷没有显着差异。可以证明含成骨细胞的可注射骨的实用性。复合材料的致密微观结构和最不理想的初始血管形成可能解释了骨形成的缺乏。为了提高成骨细胞存活率,必须进行修改,以作为可注射成骨性骨替代系统的可能应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号